ECSP11010838A - Derivados de benzazepina y sus usos como antagonistas de histamina h3 - Google Patents
Derivados de benzazepina y sus usos como antagonistas de histamina h3Info
- Publication number
- ECSP11010838A ECSP11010838A EC2011010838A ECSP11010838A ECSP11010838A EC SP11010838 A ECSP11010838 A EC SP11010838A EC 2011010838 A EC2011010838 A EC 2011010838A EC SP11010838 A ECSP11010838 A EC SP11010838A EC SP11010838 A ECSP11010838 A EC SP11010838A
- Authority
- EC
- Ecuador
- Prior art keywords
- alkyl
- cycloalkyl
- heterocyclyl
- alkylene
- aryl
- Prior art date
Links
- 239000000739 antihistaminic agent Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 125000000623 heterocyclic group Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 6
- 125000002947 alkylene group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000004450 alkenylene group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- -1 cyano, amino Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000003047 N-acetyl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000004108 n-butyl group Chemical class [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Un compuesto que tiene la fórmula (1) en donde:R1 es un grupo seleccionado de C3-8 cicloalquilo, C1-6 alquilo, C1-6 alquileno-C3-8 cicloalquilo, cada uno de los cuales puede ser opcionalmente sustituido con C1-6 alquilo, halógeno, haloC1-6 alquilo o OR15, o R1 es heterociclilo, opcionalmente sustituido con C1-6 alquilo, haloC1-6 alquilo o OR15;n es 0, 1, 2, 3 o 4, el grupo alquileno -(CH2)n- formado de ese modo, siendo opcionalmente sustituido con un grupo seleccionado de C1-4 alquilo, C3-8 cicloalquilo y arilsulfonilo;A es un grupo seleccionado de -N(R2)CO-, -CON(R2)-, -OC(O)-, -C(O)O-, -CO-, -C(R2)(OR3)-, -C(=N-O-R3)-, -C(=CR2R3)-, -C3-8 cicloalquileno-, -C(R2)(haloC1-6 alquilo)-, C1-4 alquileno y -C(OR3)(haloC1-6 alquilo)-;R2 y R3 cada uno son independientemente seleccionados de H, C1-6 alquilo, y C3-8 cicloalquilo, o cuando A es -N(R2)CO- y X está ausente, R2 puede formar, junto con el átomo de nitrógeno adyacente y Z, un grupo heterociclilo que contiene N, el cual puede ser sustituido opcionalmente;X está ausente o es C1-4 alquileno o C2-4 alquenileno, cada uno de los cuales puede ser opcionalmente sustituido con uno o más grupos C1-4 alquilo, OR16, halógeno o haloC1-6 alquilo;Z es seleccionado de arilo, heteroarilo, C3-8 cicloalquilo, y heterociclilo, cada uno de los cuales puede ser opcionalmente sustituido por un grupo seleccionado de -Y-arilo, -Y-heteroarilo, -Y-C3-8 cicloalquilo y -Y-heterociclilo, o cuando X está presente, Z puede ser H, o cuando X está ausente y A es -C(R2)(OR3)- o -N(R2)CO-, Z puede ser H, o cuando A es -N(R2)CO- y X está ausente, Z puede formar, junto con el átomo de nitrógeno adyacente y R2, un grupo heterociclilo que contiene N, el cual puede ser opcionalmente sustituido, en donde, cuando A es -CO-, Z está ligado a X o A via un átomo de carbono y en donde, cuando A es -N(R2)CO- y Z es H, R1 es C3-8 cicloalquilo; yY representa un enlace, C1-6 alquileno, CO, NR14, COC2-6 alquenileno, O, SO2 o NHCOC1-6 alquileno;en donde dichos grupos Z cicloalquilo, arilo, heteroarilo y heterociclilo pueden ser opcionalmente sustituidos por uno o más sustituyentes, los cuales pueden ser los mismos o diferentes y los cuales son seleccionados de halógeno, haloC1-6 alquilo, hidroxi, ciano, nitro, =O, -R4, -CO2R4, -COR4, -NR5R6, -C1-6 alquilo-NR5R6, -C3-8 cicloalquilo-NR5R6, -CONR12R13, -NR12COR13, -NR5SO2R6, -OCONR5R6, -NR5CO2R6, -NR4CONR5R6 o -SO2NR5R6-SHR8, -alquilo-OR8, -SOR8, -OR9, -SO2R9, -OSO2R9, -alquilo-SO2R9, -alquilo-CONHR9, -alquilo-SONHR9, -alquilo-COR10, -CO-alquilo-R10, -O-alquilo-R11 (en donde R4, R5 y R6 representan hidrógeno independientemente, C1-6 alquilo, -C3-8 cicloalquilo, -C1-6 alquileno-C3-8 cicloalquilo, aril, heterociclilo o heteroaril, en donde R8 representa C1-6 alquilo, en donde R9 representa C1-6 alquilo o arilo, en donde R10 representa aril, en donde R11 representa C3-8 cicloalquilo o aril, R12, R13, R14, R15 y R16 cada uno independientemente representa H o C1-6 alquilo, y en donde -NR5R6 y -NR12R13 pueden representar un grupo heterociclilo que contiene nitrógeno); en donde dichos grupos R4, R5, R6 R8, R9, R10 y R11 pueden ser opcionalmente sustituidos por uno o más sustituyentes, los cuales pueden ser los mismos o diferentes, y los cuales se han seleccionado del grupo que consiste en halógeno, hidroxi, C1-6 alquilo, C1-6 alcoxi, ciano, amino, =O o trifluorometilo;y en donde los sustituyentes de Z seleccionados de -Y-arilo -Y-heteroarilo, -Y-C3-8cicloalquilo y -Y-heterociclilo pueden ser opcionalmente sustituidos por uno o más sustituyentes seleccionados de =O, hidroxi, ciano, nitro, halógeno, haloC1-6 alquilo y C1-6 alquilo;y en donde, cuando A es C1-4 alquileno, dicho grupo Z cicloalquilo, arilo, heteroarilo o heterociclilo (como un grupo Z heterociclilo) es sustituido al menos con hidroxi, CF3, o =O;y en donde, cuando A es CON(R2) n es 1;o una sal aceptable para uso farmacéutico o un éster de la misma,siempre que: cuando A es -CO-, R1 es CH3, C3-8 cicloalquilo-sustituido C1-6 alquileno o n-butil, n es 0 y X es -CH2CH2-, Z no sea N-benzil sustituido 4-piperidinilo, N-(3-fluorobenzil)-sustituido 4-piperidinilo o N-acetil sustituido 4-piperidinilo;cuando A es -OC(O)-, R1 es ciclobutilo, n es 0 y X es -CH2CH2-, Z no sea H;cuando A es -OC(O)-, R1 es n-propilo, n es 0 y X es -CH2-, Z no sea H; ycuando A es -CO-, R1 es CH3, n es 0 y X es CH2, Z no sea H.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0813254A GB0813254D0 (en) | 2008-07-18 | 2008-07-18 | Compounds and their use |
| GB0905231A GB0905231D0 (en) | 2009-03-26 | 2009-03-26 | Compounds and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11010838A true ECSP11010838A (es) | 2011-05-31 |
Family
ID=41051104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011010838A ECSP11010838A (es) | 2008-07-18 | 2011-02-18 | Derivados de benzazepina y sus usos como antagonistas de histamina h3 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20110124626A1 (es) |
| EP (1) | EP2326625A1 (es) |
| JP (1) | JP2011528341A (es) |
| KR (1) | KR20110036044A (es) |
| CN (1) | CN102099339A (es) |
| AU (1) | AU2009272486A1 (es) |
| CA (1) | CA2731196A1 (es) |
| CL (1) | CL2011000043A1 (es) |
| CO (1) | CO6341614A2 (es) |
| CR (1) | CR20110049A (es) |
| DO (1) | DOP2011000015A (es) |
| EA (1) | EA201170196A1 (es) |
| EC (1) | ECSP11010838A (es) |
| GE (1) | GEP20125590B (es) |
| IL (1) | IL210722A0 (es) |
| MA (1) | MA32550B1 (es) |
| MX (1) | MX2011000460A (es) |
| PE (1) | PE20110408A1 (es) |
| WO (1) | WO2010007382A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2655604C (en) | 2006-06-23 | 2016-08-09 | Abbott Laboratories | Cyclopropyl amine derivatives |
| US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| EP2942346B1 (en) | 2009-02-17 | 2020-05-06 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as cxcr2 modulators |
| WO2010110378A1 (ja) | 2009-03-26 | 2010-09-30 | 武田薬品工業株式会社 | ピラゾール化合物 |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| WO2011083316A1 (en) * | 2010-01-08 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Benzazepine derivatives for the treatment of central nervous system disorders |
| AR079851A1 (es) * | 2010-01-08 | 2012-02-22 | Takeda Pharmaceutical | Derivados de benzazepina para tratamiento de desordenes en el sistema nervioso central |
| WO2011083315A1 (en) | 2010-01-08 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Compounds and their use |
| JP5766278B2 (ja) | 2010-05-11 | 2015-08-19 | サノフイ | 置換されたｎ−アルキルおよびｎ−アシルテトラヒドロ−イソキノリン誘導体、それらの製造および治療上の使用 |
| AR081034A1 (es) * | 2010-05-11 | 2012-05-30 | Sanofi Aventis | Derivados de n-heteroaril tetrahidro-isoquinolina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central |
| EP2569294B1 (en) | 2010-05-11 | 2015-03-11 | Sanofi | Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof |
| TW201206939A (en) | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof |
| AR081908A1 (es) | 2010-05-11 | 2012-10-31 | Sanofi Aventis | N-heteroaril-espirolactama-bipirrolidinas sustituidas, preparacion y usos terapeuticos de las mismas |
| WO2011143161A1 (en) | 2010-05-11 | 2011-11-17 | Sanofi | Substituted n-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof |
| AU2011293612B2 (en) * | 2010-08-23 | 2015-11-26 | Syntrix Biosystems Inc. | Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators |
| US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| US8969365B2 (en) | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
| US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| US10266515B2 (en) | 2013-12-30 | 2019-04-23 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| KR102286305B1 (ko) * | 2014-07-16 | 2021-08-09 | 라이프에스씨아이 파마슈티컬스, 인크. | 치료적 억제 화합물 |
| WO2016075239A1 (en) * | 2014-11-14 | 2016-05-19 | Boehringer Ingelheim International Gmbh | Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (sstr4) agonists |
| GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
| WO2018011628A1 (en) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| GB201617758D0 (en) * | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| BR112020009361A2 (pt) | 2017-11-17 | 2020-10-13 | Cellix Bio Private Limited | composto de fórmula i, composição farmacêutica para tratar um distúrbio ocular ou complicações do mesmo, método de síntese de composto, método de tratamento de um distúrbio ocular ou complicações do mesmo em um indivíduo que precisa do mesmo e uso de um composto |
| CN114736195B (zh) * | 2022-03-01 | 2022-11-15 | 天水师范学院 | 一种氧硫杂环戊烷-苯并香豆素化合物及其制备方法和作为荧光探针的用途 |
| CN119997982A (zh) | 2022-09-09 | 2025-05-13 | 迈里克斯制药有限公司 | 包含nmt抑制剂的抗体药物偶联物及其用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW197435B (es) * | 1990-11-22 | 1993-01-01 | Takeda Pharm Industry Co Ltd | |
| PT1285651E (pt) * | 2000-04-28 | 2010-10-21 | Takeda Pharmaceutical | Antagonistas da hormona concentradora da melanina |
| EP1283199A4 (en) * | 2000-05-16 | 2003-12-17 | Takeda Chemical Industries Ltd | MELANINE CONCENTRATING HORMONE ANTAGONISTS |
| AR035369A1 (es) * | 2000-11-14 | 2004-05-12 | Smithkline Beecham Plc | Derivados de tetrahidrobenzazepina composiciones farmaceuticas que los comprenden, el uso de dichos derivados en la fabricacion de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos |
| WO2004113300A1 (ja) * | 2003-06-23 | 2004-12-29 | Ono Pharmaceutical Co., Ltd. | 新規三環性複素環化合物 |
| JPWO2005040135A1 (ja) * | 2003-10-24 | 2007-03-08 | 小野薬品工業株式会社 | 抗ストレス薬およびその医薬用途 |
| GB0329214D0 (en) * | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
| US8207160B2 (en) * | 2003-12-18 | 2012-06-26 | Abbott Gmbh & Co. Kg | Tetrahydrobenzazepines and their use in he modulation of the dopamine D3 receptor |
| US20050137186A1 (en) * | 2003-12-18 | 2005-06-23 | Abbott Gmbh & Co. Kg. | Tetrahydrobenzazepines and their use |
| JPWO2005063241A1 (ja) * | 2003-12-26 | 2007-07-19 | 小野薬品工業株式会社 | ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤 |
| GB0405628D0 (en) * | 2004-03-12 | 2004-04-21 | Glaxo Group Ltd | Novel compounds |
| TW200611701A (en) * | 2004-06-18 | 2006-04-16 | Glaxo Group Ltd | Novel compounds |
| WO2006001463A1 (ja) * | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| GB0418267D0 (en) * | 2004-08-16 | 2004-09-15 | Glaxo Group Ltd | Novel compounds |
| BRPI0514504A (pt) * | 2004-08-20 | 2008-06-10 | Univ Michigan | pequenas moléculas inibidoras de membros da famìlia bcl-2 anti-apoptóticos e os usos das mesmas |
| DE102006039003A1 (de) * | 2006-08-19 | 2008-02-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Verbindungen |
| US20080159958A1 (en) * | 2006-12-27 | 2008-07-03 | Abbott Laboratories | Determination of histamine-3 bioactivity |
| AU2009225869B2 (en) * | 2008-03-18 | 2014-01-23 | Merck Sharp & Dohme Llc | Substituted 4-hydroxypyrimidine-5-carboxamides |
-
2009
- 2009-07-17 US US13/054,688 patent/US20110124626A1/en not_active Abandoned
- 2009-07-17 CA CA2731196A patent/CA2731196A1/en not_active Abandoned
- 2009-07-17 WO PCT/GB2009/001774 patent/WO2010007382A1/en not_active Ceased
- 2009-07-17 MX MX2011000460A patent/MX2011000460A/es not_active Application Discontinuation
- 2009-07-17 JP JP2011517994A patent/JP2011528341A/ja not_active Withdrawn
- 2009-07-17 KR KR1020117001319A patent/KR20110036044A/ko not_active Withdrawn
- 2009-07-17 GE GEAP200912098A patent/GEP20125590B/en unknown
- 2009-07-17 EA EA201170196A patent/EA201170196A1/ru unknown
- 2009-07-17 AU AU2009272486A patent/AU2009272486A1/en not_active Abandoned
- 2009-07-17 CN CN200980127932.XA patent/CN102099339A/zh active Pending
- 2009-07-17 EP EP09784728A patent/EP2326625A1/en not_active Withdrawn
- 2009-07-17 PE PE2011000024A patent/PE20110408A1/es not_active Application Discontinuation
-
2011
- 2011-01-07 CL CL2011000043A patent/CL2011000043A1/es unknown
- 2011-01-13 CO CO11003062A patent/CO6341614A2/es not_active Application Discontinuation
- 2011-01-14 DO DO2011000015A patent/DOP2011000015A/es unknown
- 2011-01-18 IL IL210722A patent/IL210722A0/en unknown
- 2011-01-25 CR CR20110049A patent/CR20110049A/es unknown
- 2011-02-10 MA MA33600A patent/MA32550B1/fr unknown
- 2011-02-18 EC EC2011010838A patent/ECSP11010838A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA32550B1 (fr) | 2011-08-01 |
| WO2010007382A8 (en) | 2010-03-18 |
| IL210722A0 (en) | 2011-03-31 |
| CO6341614A2 (es) | 2011-11-21 |
| DOP2011000015A (es) | 2011-04-15 |
| KR20110036044A (ko) | 2011-04-06 |
| AU2009272486A1 (en) | 2010-01-21 |
| CN102099339A (zh) | 2011-06-15 |
| MX2011000460A (es) | 2011-03-15 |
| US20110124626A1 (en) | 2011-05-26 |
| EA201170196A1 (ru) | 2011-12-30 |
| PE20110408A1 (es) | 2011-06-22 |
| JP2011528341A (ja) | 2011-11-17 |
| CL2011000043A1 (es) | 2011-10-28 |
| CA2731196A1 (en) | 2010-01-21 |
| CR20110049A (es) | 2011-06-22 |
| GEP20125590B (en) | 2012-07-25 |
| EP2326625A1 (en) | 2011-06-01 |
| WO2010007382A1 (en) | 2010-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2011000015A (es) | Derivados de benzazepina y sus usos como antagonistas h3 de histamina | |
| ES2502790T3 (es) | Moduladores de la cinasa Aurora y método de uso | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| AR064675A1 (es) | Derivados heterociclicos de pirrolo- [2,3-b] piridina, inhibidores de proteinquinasas plk, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en trastornos hiperproliferativos | |
| AR068657A1 (es) | Derivados de piperidina y piperazina | |
| AR061858A1 (es) | Compuestos heterociclicos de fosfonatos y fosfinatos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos. | |
| AR062640A1 (es) | Compuestos de azolcarboxamidas y composiciones herbicidas | |
| AR056327A1 (es) | Compuestos de nucleosidos para el tratamiento de infecciones virales | |
| AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
| CO6321130A2 (es) | Piridinas carboxamidas como inhibidores de la 11 beta-hsd1 | |
| AR073760A1 (es) | Derivados heterociclicos y metodos de uso de los mismos | |
| HRP20100542T1 (hr) | Derivati bifenila i njihova uporaba za liječenje hepatitisa c | |
| CO5611110A2 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion, composiciones farmaceuticas y usos de los mismos | |
| CO5680430A2 (es) | Derivados de 1-benzol-piperazina como inhibidores de la captacion de glicina para el ratamiento de psicosis | |
| AR056307A1 (es) | Heteroarilamidas(3.1.0)biciclicas como inhibidores del transporte de glicina de tipo i. composiciones farmaceuticas | |
| AR061946A1 (es) | Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas, su preparacion y composiciones farmaceuticas | |
| ECSP12012212A (es) | Derivados de ariletinilo | |
| EA200970493A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| CO6140059A2 (es) | Derivados de imidazol-pirimidina para el tratamiento de enfermedades relacionadas con la glicogeno sintasa quinasa (gsk3) | |
| AR060623A1 (es) | Compuestos derivados de 2-azetidinona y un metodo de preparacion | |
| CO6210701A2 (es) | Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxilico | |
| AR072047A1 (es) | Compuestos heterociclicos utiles para inhibir la adn girasa | |
| AR076235A1 (es) | Compuestos organicos y sus usos | |
| BR112016004593B1 (pt) | Métodos para reagir um composto, para hidrolisar um composto ou um sal do mesmo, para produzir um composto e para preparar um composto |